In this double-blind , randomized , placebo-controlled clinical trial , we evaluated systemic and mucosal immune responses to a candidate adenovirus serotype 26 ( Ad26 ) vectored HIV-1 envelop ( Env ) vaccine in baseline Ad26-seronegative and Ad26-seropositive healthy volunteers .